Cargando…

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/H...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Arcangelo, Manolo, Cappuzzo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593708/
https://www.ncbi.nlm.nih.gov/pubmed/23493885
http://dx.doi.org/10.2147/BTT.S28908
_version_ 1782262279678459904
author D’Arcangelo, Manolo
Cappuzzo, Federico
author_facet D’Arcangelo, Manolo
Cappuzzo, Federico
author_sort D’Arcangelo, Manolo
collection PubMed
description Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC.
format Online
Article
Text
id pubmed-3593708
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35937082013-03-14 Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer D’Arcangelo, Manolo Cappuzzo, Federico Biologics Review Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC. Dove Medical Press 2013 2013-03-03 /pmc/articles/PMC3593708/ /pubmed/23493885 http://dx.doi.org/10.2147/BTT.S28908 Text en © 2013 D’Arcangelo and Cappuzzo, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
D’Arcangelo, Manolo
Cappuzzo, Federico
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
title Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
title_full Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
title_fullStr Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
title_full_unstemmed Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
title_short Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
title_sort focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593708/
https://www.ncbi.nlm.nih.gov/pubmed/23493885
http://dx.doi.org/10.2147/BTT.S28908
work_keys_str_mv AT darcangelomanolo focusonthepotentialroleofficlatuzumabinthetreatmentofnonsmallcelllungcancer
AT cappuzzofederico focusonthepotentialroleofficlatuzumabinthetreatmentofnonsmallcelllungcancer